Still, despite costs largely in line with the therapy's benefits, the study's author and another expert said reimbursement models have not kept up and need improvement.
A manufacturing error during a clinical trial of Kymriah, now marketed by Novartis, is less likely today, but could be an issue as CAR-Ts move into earlier therapy lines.
Explore the top mobile IV therapy companies boosting immune health on demand, with standout services, expert care and innovative delivery across the U.S.
In a first, the agency approved Adaptive Biotechnologies' clonoSEQ assay to detect MRD in acute lymphoblastic leukemia and multiple myeloma, a measure that can predict risk of relapse.